The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis

Carcinogenesis

Volumn 17, Issue 3, 1996, Pages 585-594

  Dragan, Y P ^a   Fahey, S ^b   Nuwaysir, E ^a   Sattler, C ^a   Babcock, K ^a   Vaughan, J ^a   McCague, R ^c   Jordan, V C ^d   Pitot, H C ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Hazelton Laboratories ^*  (United States)

^c ChiroTech   (United Kingdom)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLNITROSAMINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; ESTROGEN ACTIVITY; FEMALE; HISTOPATHOLOGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RAT; STEREOLOGY; UTERUS WEIGHT;

ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; DIETHYLNITROSAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FEMALE; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICROBODIES; ORGAN SIZE; RATS; RATS, INBRED F344; TAMOXIFEN; UTERUS;

EID: 0029865172     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.3.585     Document Type: Article

References (106)

1. Buchanan,R , Blamey,R., Durrant,K., Howell,A., Paterson,A., Preese,P., Smith,D., Williams,C. and Wilson,R. (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin. Oncol., 4, 1326-1330.
2. Cole,M., Jones,C and Todd,I. (1971) A new anti-estrogenic agent in late breast cancer: an early clinical appraisal of ICI 46.474. Br. J. Cancer. 25, 270-275
3. Ingle,J., Krook,J., Green,S. et al. (1986) Randomized trial of bilateral oophorectomy versus lamoxifen in premenopausal women with metastatic breast cancer. J. Clin. Oncol , 4, 178-185.
4. Sawka,C., Pritchard,K., Paterson,D. and Sutherland,D. (1986) Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res , 46, 3152-3156.
5. Tormey,D., Simon,R , Lippman,M., Bull,J. and Myers,C (1976) Evaluation of tamoxifen in advanced breast cancer: a progress report. Cancer Treatment Rep., 60, 1451-1459.
6. Ward,H. (1973) Antiestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J , i, 13-14.
7. Furr,B.J.A. and Jordan,V.C. (1984) The pharmacology and clinical uses of tamoxifen. Ther. Pharmacol., 25, 127-205.
8. Early Breast Trials Cooperative Group. (1988) Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. New Engl. J. Med , 319, 1681-1692.
9. Tormey,D and Jordan,V. (1984) Long-term tamoxifen adjuvant therapy in node positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res. Treatment, 4, 297-302.
10. Delozier,T, Julien,J., Juret,P., Vegret,C., Couette,J.-E., Graic,Y., Ollivier,J.-M. and de Ranien,E. (1986) Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Treatment, 7, 105-110.
11. Fentiman,I. and Powles,T. (1987) Tamoxifen and benign breast problems. Lancet, ii, 1070-1072
12. Fischer,B., Constantino,J., Redmond,C et al. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumors. New Engl. J. Med., 320, 479-484.
13. Powles,T., Jones,A., Ashley,S. et al. (1994) The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treatment, 31, 73-82.
14. Vanchien,C. (1992) Breast cancer study initiated in Italy. J. Natl Cancer Inst., 84, 1555-1556.
15. Fischer,B., Brown,A., Wolmark,N. et al. (1987) Prolonging tamoxifen therapy for primary breast cancer. Annls Internal Med., 106, 649-654.
16. Jordan,V.C. (1990) Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res. Treatment, 15, 125-136.
17. Love,R., Newcomb,P., Wiebe,D., Surawicz,T., Jordan,V., Carbone,P. and DeMets.D. (1990) Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node nesative disease. J. Natl Cancer Inst., 82, 1327-1332.
18. Fornander,T., Rutqvist,L., Sjoberg,H., Blomqvist,L., Mattison,A. and Glas,U. (1990) Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J. Clin. Oncol., 8, 1019-1024.
19. Gusberg,S.B. (1990) Tamoxifen for breast cancer: associated endometrial cancer. Cancer, 65, 1463-1464.
20. Cuzick,J., Allen,D., Baum,M. et al. (1993) Long term effects of tamoxifen. Biological effects of tamoxifen working group. Eur. J. Cancer, 29A, 15-21.
21. Catherino, W. and Jordan, V.C. (1993) Risk benefit assessment of tamoxifen therapy Drug Safety, 8, 381-397.
22. Hirsamaki,P., Hirsamaki,Y., Nieminen,L. and Payne,B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a one year study with two anti-estrogens. Arch. Toxicol., 67, 49-54.
23. Williams,G.M., Iatropoulos,M.J., Djordjevic,M.V. and Kaltenberg,O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
24. Greaves,P., Goonetilleke,R., Nunn,G., Topham,J. and Orton,T. (1993) Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res., 53, 3919-3924.
25. Sasco,A. (1991) Tamoxifen: a carcinogen as a preventive agent. Cancer J., 4, 217-218.
26. Davidson,N. (1992) Tamoxifen - panacea or Pandora's box? New Engl. J Med., 326, 885-886.
27. Williams,G., Iatropoulos,M. and Hard,G. (1992) Long-term prophylactic use of tamoxifen: is it safe? Eur. J. Cancer Prevention, 1, 386-387.
28. Fugh-Berman,A. and Epstein,S. (1992) Should healthy women take tamoxifen? New Engl. J. Med., 22, 1596.
29. Tucker,M.J., Adam,H.K. and Panerson,J.S. (1984) Tamoxifen. In Laurence,D.R., McLean,A E.M. and Wetherall,M. (eds). Safety Testing of New Drugs. Laboratory Predictions and Clinical Performance. Academic Press, London, UK, pp. 125-161
30. Mani,C. and Kupfer,D. (1991) Cytochrome P450 mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res., 51, 6052-6058.
31. Mani,C., Pearce,R , Parkinson,A. and Kufer,D. (1994) Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent bindins to rat and human liver microsomes. Carcinogenesis, 15, 2715-2720.
32. Han,X. and Liehr,J. (1992) Induction of covalent adducts in rodents by tamoxifen. Cancer Res., 52, 1360-1363.
33. White,I.N.H , de Matteis,F., Davies,A., Smith,L.L., Crofton-Sleigh,C., Venitt,S., Hewer,A. and Phillips,D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F244/n rats, DBA/2 and C57BL/6 mice and human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
34. Hard,G., Iatropoulos,M., Jordan,K., Radi,L., Kaltenberg,O , Imondi,A. and Williams,G. (1993) Major differences in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female CrL:CD(BR) rats. Cancer Res., 53, 4334-4341.
35. White,I., Davies,A., Jukes,R., Phillips,D. and de Matteis,F. (1993) A comparison of the genotoxic potential of tamoxifen and toremifene in female F344 rats. Hum. Exp. Toxicol., 12, 569.
36. Pathak,D. and Bodell,W (1994) DMA adduct formtion by tamoxifen with rat and human microsomal activation systems. Carcinogenesis, 15, 529-532.
37. Yager,J., Roebuck,B., Paluszcyk,T. and Memoli,V. (1986) Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase positive foci in female rats. Carcinogenesis, 7, 2007-2014.
38. Kohigashi,K., Fukuda,Y. and Imura,H (1988) Inhibitory effect of tamoxifen on DES-promoted hepatic tumorigenesis in male rats and its possible mechanism of action. Gann, 79, 1335-1339.
39. Ghia,M. and Mereto,E. (1989) Induction and promotion of γ-glutamyltranspeptidase-positive foci in the livers of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. Cancer Lett., 46, 195-202.
40. Dragan,Y.P., Xu,Y.H. and Pitot,H.C. (1991) Tumor promotion as a target of estrogen/anti-estrogen effects in rat hepatocarcinogenesis. Preventive Med., 20, 15-26.
41. Dragan,Y.P., Rizvi,T.A., Xu,Y.H., Hully,J.R., Maronpot,R.R., Campbell,H.A. and Pitot,H.C. (1991) An initiation-promotion assay in rat liver as a potential complement to the two-year bioassay. Fundam, Appl. Toxicol., 16, 525-547.
42. Dragan,Y.P., Fahey,S., Street,K., Vaughan,J., Jordan,V.C. and Pitot,H.C. (1994) Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res. Treatment, 31, 11-25.
43. Metzler,M. and Schiffmann,D. (1991) Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene type anti-estrogens. Am. J. Clin. Oncol., 14, S30-S35.
44. Sargent,L.M., Dragan,Y.P., Banhub,N., Wiley,J., Sattler,C., Schroeder,P., Sattler,G., Jordan,V.C. and Pitot,H.C. (1994) Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female SD rats. Cancer Res., 54, 3357-3360.
45. Taper,H.S. (1978) The effect of estradiol-17-phenylpropionate and estradiol benzoate on N-nitrosomorpholine-induced liver carcinogenesis in ovarectomized female rats. Cancer, 42, 462-467.
46. Yager,J.D. and Yager,R. (1980) Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res., 40, 3680-3685.
47. Wanless,I.R. and Medline,A. (1982) Role of estrogens as promoters of hepatic neopiasia. Lab. Invest., 46, 313-320.
48. Edmonson,H A., Reynolds,T.B. and Henderson,B. (1977) Regression of liver cell adenomas associated with oral contraceptives. Annls Internal Med., 86, 180-182.
49. Kendall,M.E. and Rose,D.P. (1992) The effects of diethylstilbesterol, tamoxifen, and toremifene on estrogen inducible hepatic protein and estrogen receptor proteins in female rats. Toxicol. Appl. Pharmacol., 114, 127-131.
50. Sakai,F., Cheix,F., Clavel,M., Colon,J., Mayer,M., Pannata,E. and Saez,S. (1978) Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J. Endocrinol., 76, 219-226.
51. Osborne,C., Coranado,E., Allred,D., Wiebe,V. and DeGregorio,M. (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and non-isomerization of trans-4 hydroxy tamoxifen. J. Natl Cancer Inst , 83, 1477-1482.
52. Williams,M., Lennard,M., Martin,I, and Tucker,G. (1994) Interindividual variation in the isomerization of 4-hydroxy tamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis, 15, 2733-2738.
53. Katzenellenbogan,J., Carlson,K. and Katzenealenbogan,B. (1985) Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. J. Steroid Biochem., 22, 589-596.
54. Harper,M.J.K. and Walpole,A.L. (1966) Contrasting endocrine activities of cis and trons isomers in a series of substituted triphenylethylenes. Nature, 21, 87.
55. Mc Cague,R., Kuroda,R., Leclercq,G. and Stoessel,S. (1986) Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-{4-[2-(dimethylamino)ethoxy]phenyl}-5H-benzocycloheptene, a nonisomerizable analogue of tamoxifen. X-ray crystallographic studies. J. Med. Chem., 29, 2053-2059.
56. McCague,R., Jarman,M., Leung,O.-T., Foster,A., Leclercq,G. and Stoessel,S. (1988) Non-isomerisable antiestrogens related to tamoxifen. J. Steroid Biochem., 31, 545-547.
57. McCague,R , Leclercq,G. and Jordan,V.C (1988) Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes. J. Med. Chem., 31, 1285-1290.
58. Murphy,C., Parker,C., McCague,R. and Jordan,V.C. (1991) Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Mol. Pharmacol., 39, 421-428.
59. Wolf,D., Langan-Fahey.S., Parker,C., McCague,R. and Jordan,V.C (1993) Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomenzable analogues of tamoxifen and metabolites. J. Natl Cancer Inst., 85, 806-812.
60. Fromson,J., Pearson,J. and Braman,S (1973) The metabolism of tamoxifen (ICI 46.474). Xenobiotica, 3, 693-709.
61. Murphy,C., Poster,T., Panzan,P., Adlercreutz,H. and Martin,F. (1987) Analysis of lamoxifen and its metabolites in human plasma by GC-MS using selected ion monitoring (SIM). J. Steroid Biochem., 26, 547-555.
62. Fromson,J., Pearson,S. and Braman,S. (1974) The metabolism of tamoxifen (ICI 46.474). Part 2. In female patients. Xenobiotica, 3, 711-714.
63. Langan-Fahey,S., Tormey,D. and Jordan,V.C. (1990) Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer, 26, 883-888.
64. Etienne,M., Milano,G., Fischel,J., Frenay,M., Francois,E., Formento,J., Gioanni,J. and Namer,M. (1989) Tamoxifen metabolism: pharmacokinetic and in vitro study. Br. J. Cancer, 60, 30-35.
65. Lien,E., Solheim,E. and Veland,P. (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Res., 51, 4837-4844.
66. Mani,C., Gelboin,H., Park,S., Pearce,R., Parkinson,A. and Kupfer,D. (1993) Metabolism of the anti-mammary cancer antiestrogen agent tamoxifen. Drug Metab. Disposal. 21, 645-656.
67. Foster,A., McCague,R., Seago,A., Leclercq,G., Stoessel,S. and Roy,F. (1986) Modification of the basic side chain in tamoxifen effects on microsomal metabolism and in vitro biological activity. Anti-Cancer Drug Design, 1, 245-257.
68. Pitot,H C., Bareness,L., Goldsworthy,T. and Kitagawa,T. (1978) Biochemical characterization of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature (Lond.), 271, 456-458.
69. Goldsworthy,T. and Pitot,H.C. (1986) An approach to the development of a short-term whole animal bioassay to distinguish imitating (incomplete) carcinogens, complete carcinogens, and noncarcinogens in the rat liver. J. Toxicol. Environ. Hlth, 16, 389-402.
70. Hendrich,S., Campbell,H, and Pitot,H.C. (1987) Quantitative stereological evaluation of four histochemical markers of altered hepatic foci in multistage hepatocarcinogenesis in the rat. Carcinogenesis, 8, 1245-1250.
71. Squire,R. and Levitt,R. (1975) Workshop on classification of specific hepatocellular lesions in the rat. Cancer Res, 35, 3214-3223.
72. Kaku,T., Ekem,J., Lindayen,C., Bailey,D., van Nostrand,A. and Farber,E. (1983) Comparison of formalin and acetone fixation for immunohistochemical detection of carcinoembryonic antigen (CEA) and keratin. Am. J. Clin Pathol., 80, 806-815.
73. Hsu,S., Raine,L. and Fanger,H. (1981) A comparative study of the peroxidase-antiperoxidase method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Clin. Pathol., 75, 734-738.
74. Satoh.K., Kitahara,A., Soma,Y., Inaha,Y., Hatayama,I. and Sato,K. (1985) Purification, induction, and distribution of PGST: a new marker enzyme for preneoplastic cells in rat chemical hepatocarcinogenesis. Proc. Natl Acad. Sci. USA, 82, 3964-3968.
75. Campbell,H., Pitot,H.C., Potter,V. and Laishes,B. (1982) Application of quantitative stereology to the evaluation of enzyme altered foci in rat liver. Cancer Res., 42, 465-472.
76. Campbell,H., Xu,Y., Hanigan,M. and Pitot,H.C. (1982) Application of quantitative stereology to the evaluation of phenotypically heterogeneous enzyme-altered foci in the rat liver. J. Natl Cancer Inst., 76, 751-767.
77. 3H]thymidine for studies of hepatocellular proliferation in rodents. Carcinogenesis, 10, 1341-1343.
78. 3H]thymidine administered by injection or osmotic minipump. Carcinogenesis, 11, 2245-2251.
79. Brown,R.R., Bain,R.R. and Jordan,V.C. (1983) Determination of tamoxifen and metabolites in human serum by high pressure liquid chromatography with post column fluorescense activation. J. Chromatogr , 272, 351-358.
80. Dabholkar,A.S. (1982) Vitamin E deficiency as hepatic peroxisomal proliferator: qualitative and quantitative electron microscopic study. Annls NY Acad. Sci., 386, 475-477.
81. Lazarow,P. (1981) Assay of peroxisomal β oxidation of fatty acids. Methods Enzymol., 72, 315-318
82. van der Hoeven,T. and Coon,M (1974) Preparation and properties of partially purified cytochrome P450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome 450 reductase from rabbit microsomes. J. Biol. Chem., 249, 6302-6310.
83. Bradford,M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
84. Sambrook,J., Fritsch,E. and Maniatis,T (1989) Molecular Cloning: A Laboratory Manual, 2nd Edn Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. pp. 12-20.
85. Pitot,H.C. (1990) Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu. Rev. Pharmacol. Toxicol., 30, 465-500.
86. Fearon,E. and Vogelstein,B. (1990) A genetic model for colorectal tumorigenesis. Cell. 60, 759-767.
87. Styles,J.A. (1993) Measurement of ploidy and cell proliferation in the rodent liver. Environ. Hlth Perspect., 101 (Suppl. 5), 67-72.
88. Carthew,P., Martin,E., White,I., de Matteis,F., Edwards,R., Dorman,B., Heydon,R. and Smith,L. (1995) Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital. Cancer Res., 55, 544-547.
89. Jordan,V.C. and Murphy,C. (1990) Endocrine pharmacology of antiestrogens as antitumor agents. Endocrinol. Rev., 11, 578-610.
90. Helgason,S., Wilking,N., Carlstron,K., Damber,M.-G. and von Schoultz,B. (1982) A comparative study of the estrogenic effects of tamoxifen and 17β estradiol in postmenopausal women. J. Clin. Endocrinol. Metab., 54, 404-408.
91. Robertson,D., Katzenellenbogen,J., Long,D , Rorke,E. and Katzenellenbogan,B. (1982) Tamoxifen antiestrogens, a comparison of the activity, pharmacokinetics. and metabolic activation of the cis and trans isomers of tamoxifen. J. Steroid Biochem., 16, 1-13.
92. Jordan,V.C. Collins,M. Rowsby,L. and Prestwich,G. (1977) A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J. Endocrinol., 75, 305-316.
93. Marsman,D , Cattley,R., Conway,J. and Popp.J. (1988) Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6(2.3 xylidino)-2-pyrimidinylthio]-acetic acid (WY-14,463) in rats. Cancer Res., 48, 6739-6744.
94. Mayol,X., Perez-Tomas,R., Cullere,X , Romero,A., Estadella,M. and Domingo,J. (1991) Cell proliferation and tumor promotion by ethinyl estradiol in rat hepatocarcinogenesis. Carcinogenesis, 12, 1133-1136.
95. Schulte-Hermann,R. (1985) Tumor promotion in the liver. Arch. Toxicol., 57, 147-158.
96. Yager,J., Zurlo,J., Sewall,C., Lucier,G. and He,H (1994) Growth stimulation followed by growth inhibition in livers of female rats treated with ethinyl estradiol. Carcinogenesis, 15, 2117-2123.
97. Bower,N., Mylecraine,L., Philbert,M. and Gallo,M. (1995) Effects of cell cycle kinetics as a possible mechanism of estradiol promotion of hepatocarcinogenesis. Toxicologist, 15, 200 (A1069).
98. Schulte-Hermann,R., Bursch,W., Kraupp-Grasl,B., Oberhammer,F , Wagner,A. and Jirtle,R. (1993) Cell proliferation and apoptosis in normal liver and preneoplastic foci. Environ. Hlth Perspect., 101 (Suppl. 5), 87-90.
99. Hirsimaki,R, Hirsamaki,Y. and Nieminen,L. (1988) The effects of tamoxifen citrate and toremifene citrate on the ultrastructure of the rat liver. Inst. Phys. Conf. Ser., 3, 235-236.
100. Neal,C., Thomassen,M. and Osmundsen,H. (1980) Induction of peroxisomal β-oxidation in rat liver by high fat diets. Biochem. J., 186, 369-371.
101. Berge,R., Nilsson,A. and Husoy,A.-M. (1988) Rapid stimulation of liver palmitoyl-CoA synthetase. carnitine palmitoyltransferase and glycerophosphate acyltransferase compared to peroxisomal β-oxidation and palmitoyl-CoA hydrolase in rats fed high-fat diets. Biochim. Biophys. Acta, 960, 417-126.
102. DeGregorio,M., Coronado,E and Osbome,C. (1989) Tumor and serum tamoxifen concentrations in the athymic nude mouse. Cancer Chemother. Pharmacol., 23, 68-70
103. Iino,Y., Wolf,D., Langan-Fahey,S., Johnson,D., Ricchio,M., Thompson,M. and Jordan,V.C. (1991) Reversible control of estradiol-stimulated growth of MCF-7 tumors by tamoxifen in the athymic nude mouse. Br. J. Cancer. 64, 1019-1024.
104. Darnel,P., Gaskell,S., Bishop,H., Campbell,C. and Nicholson,R. (1981) Determination of tamoxifen and biologically active metabolites in human breast tumors and plasma. Eur J. Clin. Oncol., 17, 1183-1189.
105. White,I., Davies,A., Smith,L., Dawson,S. and de Matteis,F. (1993) Induction of CYP2B1 and 3A1. and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol., 45, 21-30.
106. Nuwaysir,E, Dragan,Y. Jefcoate,C., Jordan,VC. and Pitot,H.C. (1995) Effect of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res., 55, 1780-1786.